JP2014523884A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014523884A5 JP2014523884A5 JP2014517251A JP2014517251A JP2014523884A5 JP 2014523884 A5 JP2014523884 A5 JP 2014523884A5 JP 2014517251 A JP2014517251 A JP 2014517251A JP 2014517251 A JP2014517251 A JP 2014517251A JP 2014523884 A5 JP2014523884 A5 JP 2014523884A5
- Authority
- JP
- Japan
- Prior art keywords
- edc
- antibody
- targeting moiety
- composition
- therapeutic agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000008685 targeting Effects 0.000 claims description 38
- 239000003814 drug Substances 0.000 claims description 34
- 229940124597 therapeutic agent Drugs 0.000 claims description 24
- 210000004027 cell Anatomy 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 11
- -1 Sel-1 Proteins 0.000 claims description 10
- 229940079593 drug Drugs 0.000 claims description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
- 201000010099 disease Diseases 0.000 claims description 7
- 230000000694 effects Effects 0.000 claims description 7
- 102100033400 4F2 cell-surface antigen heavy chain Human genes 0.000 claims description 6
- 102100032412 Basigin Human genes 0.000 claims description 6
- 102100032912 CD44 antigen Human genes 0.000 claims description 6
- 101000800023 Homo sapiens 4F2 cell-surface antigen heavy chain Proteins 0.000 claims description 6
- 101000798441 Homo sapiens Basigin Proteins 0.000 claims description 6
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 claims description 6
- 101000605020 Homo sapiens Large neutral amino acids transporter small subunit 1 Proteins 0.000 claims description 6
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 claims description 6
- 101000760337 Homo sapiens Urokinase plasminogen activator surface receptor Proteins 0.000 claims description 6
- 102100025818 Major prion protein Human genes 0.000 claims description 6
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 claims description 6
- 102100024689 Urokinase plasminogen activator surface receptor Human genes 0.000 claims description 6
- 102000004169 proteins and genes Human genes 0.000 claims description 6
- 108090000623 proteins and genes Proteins 0.000 claims description 6
- 102000008873 Angiotensin II receptor Human genes 0.000 claims description 4
- 108050000824 Angiotensin II receptor Proteins 0.000 claims description 4
- 102100026144 Transferrin receptor protein 1 Human genes 0.000 claims description 4
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims description 2
- 102100022738 5-hydroxytryptamine receptor 1A Human genes 0.000 claims description 2
- 101710138638 5-hydroxytryptamine receptor 1A Proteins 0.000 claims description 2
- 108091023037 Aptamer Proteins 0.000 claims description 2
- 102100024210 CD166 antigen Human genes 0.000 claims description 2
- 101000975407 Caenorhabditis elegans Inositol 1,4,5-trisphosphate receptor itr-1 Proteins 0.000 claims description 2
- 101000975393 Drosophila melanogaster Inositol 1,4,5-trisphosphate receptor Proteins 0.000 claims description 2
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 claims description 2
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 claims description 2
- 108091008794 FGF receptors Proteins 0.000 claims description 2
- 102000027484 GABAA receptors Human genes 0.000 claims description 2
- 108091008681 GABAA receptors Proteins 0.000 claims description 2
- 101000980840 Homo sapiens CD166 antigen Proteins 0.000 claims description 2
- 101001034652 Homo sapiens Insulin-like growth factor 1 receptor Proteins 0.000 claims description 2
- 101001139093 Homo sapiens Klotho Proteins 0.000 claims description 2
- 101000937642 Homo sapiens Malonyl-CoA-acyl carrier protein transacylase, mitochondrial Proteins 0.000 claims description 2
- 101000590830 Homo sapiens Monocarboxylate transporter 1 Proteins 0.000 claims description 2
- 101000724418 Homo sapiens Neutral amino acid transporter B(0) Proteins 0.000 claims description 2
- 101000692455 Homo sapiens Platelet-derived growth factor receptor beta Proteins 0.000 claims description 2
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 claims description 2
- 101000835093 Homo sapiens Transferrin receptor protein 1 Proteins 0.000 claims description 2
- 108010001127 Insulin Receptor Proteins 0.000 claims description 2
- 102100036721 Insulin receptor Human genes 0.000 claims description 2
- 102100039688 Insulin-like growth factor 1 receptor Human genes 0.000 claims description 2
- 102100020686 Klotho Human genes 0.000 claims description 2
- 102100024032 Linker for activation of T-cells family member 1 Human genes 0.000 claims description 2
- 101710138751 Major prion protein Proteins 0.000 claims description 2
- 102100027329 Malonyl-CoA-acyl carrier protein transacylase, mitochondrial Human genes 0.000 claims description 2
- 206010027476 Metastases Diseases 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 102100028267 Neutral amino acid transporter B(0) Human genes 0.000 claims description 2
- 208000034038 Pathologic Neovascularization Diseases 0.000 claims description 2
- 101710096328 Phospholipase A2 Proteins 0.000 claims description 2
- 102100026918 Phospholipase A2 Human genes 0.000 claims description 2
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 claims description 2
- 108010025832 RANK Ligand Proteins 0.000 claims description 2
- 102000014128 RANK Ligand Human genes 0.000 claims description 2
- 108091006232 SLC7A5 Proteins 0.000 claims description 2
- 102000019208 Serotonin Plasma Membrane Transport Proteins Human genes 0.000 claims description 2
- 108010012996 Serotonin Plasma Membrane Transport Proteins Proteins 0.000 claims description 2
- 108091008874 T cell receptors Proteins 0.000 claims description 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims description 2
- 102100039360 Toll-like receptor 4 Human genes 0.000 claims description 2
- 108050003222 Transferrin receptor protein 1 Proteins 0.000 claims description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 2
- 208000036142 Viral infection Diseases 0.000 claims description 2
- 230000006907 apoptotic process Effects 0.000 claims description 2
- 230000001580 bacterial effect Effects 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 208000035475 disorder Diseases 0.000 claims description 2
- 102000052178 fibroblast growth factor receptor activity proteins Human genes 0.000 claims description 2
- 230000002538 fungal effect Effects 0.000 claims description 2
- 208000015181 infectious disease Diseases 0.000 claims description 2
- 208000027866 inflammatory disease Diseases 0.000 claims description 2
- 102000006495 integrins Human genes 0.000 claims description 2
- 108010044426 integrins Proteins 0.000 claims description 2
- 208000028867 ischemia Diseases 0.000 claims description 2
- 230000001404 mediated effect Effects 0.000 claims description 2
- 230000009401 metastasis Effects 0.000 claims description 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 2
- 230000019491 signal transduction Effects 0.000 claims description 2
- 125000002345 steroid group Chemical group 0.000 claims description 2
- 229940126585 therapeutic drug Drugs 0.000 claims description 2
- 230000009385 viral infection Effects 0.000 claims description 2
- 230000003612 virological effect Effects 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 17
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161500756P | 2011-06-24 | 2011-06-24 | |
| US61/500,756 | 2011-06-24 | ||
| US201161507882P | 2011-07-14 | 2011-07-14 | |
| US61/507,882 | 2011-07-14 | ||
| US201161551287P | 2011-10-25 | 2011-10-25 | |
| US61/551,287 | 2011-10-25 | ||
| PCT/US2012/044029 WO2012178173A1 (en) | 2011-06-24 | 2012-06-25 | Extracellular targeted drug conjugates |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014523884A JP2014523884A (ja) | 2014-09-18 |
| JP2014523884A5 true JP2014523884A5 (https=) | 2015-08-13 |
Family
ID=47423002
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014517251A Pending JP2014523884A (ja) | 2011-06-24 | 2012-06-25 | 細胞外標的化薬物複合体 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20140193436A1 (https=) |
| EP (1) | EP2723393A4 (https=) |
| JP (1) | JP2014523884A (https=) |
| CN (2) | CN107080847A (https=) |
| WO (1) | WO2012178173A1 (https=) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2382990T3 (pl) | 2003-04-30 | 2015-04-30 | Univ Zuerich | Sposoby leczenia raka z zastosowaniem immunotoksyny |
| WO2015048901A1 (en) | 2013-10-02 | 2015-04-09 | Viventia Bio Inc. | Anti-epcam antibodies and methods of use |
| CN106456748A (zh) * | 2014-01-08 | 2017-02-22 | 小利兰·斯坦福大学托管委员会 | 小细胞肺癌的靶向疗法 |
| JP2017506640A (ja) * | 2014-02-14 | 2017-03-09 | セントローズ， エルエルシー | 細胞外標的化薬物共役体 |
| JP2017114763A (ja) * | 2014-03-26 | 2017-06-29 | 第一三共株式会社 | 抗ｃｄ９８抗体−薬物コンジュゲート |
| CN107580501A (zh) | 2015-03-12 | 2018-01-12 | 维文蒂亚生物公司 | 用于靶向epcam阳性膀胱癌的给药策略 |
| CA2979394A1 (en) * | 2015-03-12 | 2016-09-15 | Viventia Bio Inc. | Methods of treatment for epcam positive bladder cancer |
| US20190008983A1 (en) | 2015-07-31 | 2019-01-10 | James R. Prudent | Extracellular drug conjugates targeting cd20 |
| EP3417877A4 (en) * | 2016-02-18 | 2019-10-02 | Kyoto University | FOR INHIBITING THE GENETIC FUNCTION IN EXOSOM COMPLEX AND CANCER REPRODUCTION AND / OR METASTASE UPPRESSOR |
| KR101923624B1 (ko) * | 2016-07-28 | 2018-11-30 | 고려대학교 산학협력단 | 암세포 화학요법을 위한 agtr1 압타머-항암약물 복합체 |
| EP3735427A4 (en) * | 2018-01-05 | 2021-09-15 | Immunext Inc. | ANTI-MCT1 ANTIBODIES AND USES THEREOF |
| CA3092472A1 (en) * | 2018-03-02 | 2019-09-06 | Evonik Operations Gmbh | In vitro method for detecting intestinal barrier failure in animals |
| WO2019183375A1 (en) * | 2018-03-22 | 2019-09-26 | Eureka Therapeutics, Inc. | Antibody agents specifically recognizing monocarboxylate transporter 4 and uses thereof |
| AU2019247748A1 (en) | 2018-04-03 | 2020-10-08 | Ginkgo Bioworks, Inc. | Antibody-evading virus vectors |
| EP3774852A1 (en) | 2018-04-03 | 2021-02-17 | Stridebio, Inc. | Antibody-evading virus vectors |
| MX2020010465A (es) | 2018-04-03 | 2021-01-08 | Vectores de virus para direccionamiento a tejidos oftalmicos. | |
| US11168141B2 (en) | 2018-08-02 | 2021-11-09 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| CA3108282A1 (en) | 2018-08-02 | 2020-02-06 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US12018087B2 (en) | 2018-08-02 | 2024-06-25 | Dyne Therapeutics, Inc. | Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject |
| US12097263B2 (en) | 2018-08-02 | 2024-09-24 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| SG11202100928QA (en) | 2018-08-02 | 2021-02-25 | Dyne Therapeutics Inc | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| US12370264B1 (en) | 2018-08-02 | 2025-07-29 | Dyne Therapeutics, Inc. | Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject |
| US11911484B2 (en) | 2018-08-02 | 2024-02-27 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| IL280536B2 (en) * | 2018-08-02 | 2024-12-01 | Dyne Therapeutics Inc | Complexes targeting transferrin receptor and uses thereof |
| JP7671988B2 (ja) * | 2018-12-20 | 2025-05-07 | ウニヴェルズィテート バーゼル | 転移の予防又は治療において使用するためのＮａ＋／Ｋ＋ＡＴＰアーゼ阻害剤 |
| CA3140049A1 (en) | 2019-05-14 | 2020-11-19 | Duke University | Compositions and methods for the treatment of atpase-mediated diseases |
| WO2020236755A2 (en) * | 2019-05-17 | 2020-11-26 | Ionis Pharmaceuticals, Inc. | Angiotensin ii type 1 receptor targeted oligonucleotides and uses thereof |
| JP2022551739A (ja) | 2019-10-17 | 2022-12-13 | ストライドバイオ，インコーポレイテッド | ニーマン・ピック病ｃ型の治療のためのアデノ随伴ウイルスベクター |
| US12611436B2 (en) | 2019-10-17 | 2026-04-28 | Sarepta Therapeutics, Inc. | AAV transfer cassette |
| AU2021328475A1 (en) | 2020-08-19 | 2023-03-16 | Sarepta Therapeutics, Inc. | Adeno-associated virus vectors for treatment of Rett syndrome |
| CN114917329B (zh) * | 2021-02-11 | 2023-07-21 | 兰州大学第二医院 | 抗cd87抗体与抗pd1抗体联合治疗胃癌 |
| WO2022178754A1 (en) * | 2021-02-25 | 2022-09-01 | Shanghai Allygen Biologics Co., Ltd. | Targeting conjugates with therapeutic agents and oligonucleotides and uses thereof |
| US11771776B2 (en) | 2021-07-09 | 2023-10-03 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| JP2024525608A (ja) | 2021-07-09 | 2024-07-12 | ダイン セラピューティクス，インコーポレーテッド | ジストロフィン異常症を処置するための筋標的化複合体および製剤 |
| US11638761B2 (en) | 2021-07-09 | 2023-05-02 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy |
| US11969475B2 (en) | 2021-07-09 | 2024-04-30 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| US11633498B2 (en) | 2021-07-09 | 2023-04-25 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US11672872B2 (en) | 2021-07-09 | 2023-06-13 | Dyne Therapeutics, Inc. | Anti-transferrin receptor antibody and uses thereof |
| US12465647B2 (en) * | 2021-08-05 | 2025-11-11 | Sanegene Bio Usa Inc. | 1′-alkyl modified ribose derivatives and methods of use |
| TWI842088B (zh) | 2021-09-14 | 2024-05-11 | 美商伊穆諾米塔博立森發展公司 | 人類單羧酸鹽轉運蛋白1抗體及其用途 |
| IL316143A (en) | 2022-04-15 | 2024-12-01 | Dyne Therapeutics Inc | Muscle targeting complexes and formulations for the treatment of myotonic dystrophy |
| CN117430697A (zh) * | 2022-07-21 | 2024-01-23 | 佰舟生物科技(苏州)有限公司 | 抗mct1抗体及其用途 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002063299A1 (en) * | 2001-02-05 | 2002-08-15 | Graffinity Pharmaceuticals Ag | Low affinity screening method |
| CN109045307A (zh) * | 2004-06-01 | 2018-12-21 | 健泰科生物技术公司 | 抗体-药物偶联物和方法 |
| JP2009529522A (ja) * | 2006-03-10 | 2009-08-20 | ディアト | 酵素で切断可能なリンカーを介して抗体に複合された抗癌剤 |
| US8865875B2 (en) * | 2007-08-22 | 2014-10-21 | Medarex, L.L.C. | Site-specific attachment of drugs or other agents to engineered antibodies with C-terminal extensions |
| US8007808B2 (en) * | 2008-04-04 | 2011-08-30 | The Board Of Trustees Of The Univeristy Of Illinois | Composition and method for facilitating the internalization of a therapeutic agent into a cell |
| CN102316898A (zh) * | 2008-09-29 | 2012-01-11 | 森托科尔奥索生物科技公司 | 抗cd147抗体、方法和用途 |
| JP2013504585A (ja) * | 2009-09-09 | 2013-02-07 | セントローズ， エルエルシー | 細胞外標的化薬物複合体 |
| CN102573895A (zh) * | 2009-09-24 | 2012-07-11 | 埃克斯生物科技公司 | 减少抗-抗体反应的方法、组合物和试剂盒 |
| KR20130009760A (ko) * | 2010-02-10 | 2013-01-23 | 이뮤노젠 아이엔씨 | Ｃｄ２０ 항체 및 이의 용도 |
-
2012
- 2012-06-25 CN CN201610948368.XA patent/CN107080847A/zh active Pending
- 2012-06-25 EP EP12803197.8A patent/EP2723393A4/en not_active Withdrawn
- 2012-06-25 JP JP2014517251A patent/JP2014523884A/ja active Pending
- 2012-06-25 WO PCT/US2012/044029 patent/WO2012178173A1/en not_active Ceased
- 2012-06-25 CN CN201280039499.6A patent/CN103732259A/zh active Pending
- 2012-06-25 US US14/128,429 patent/US20140193436A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014523884A5 (https=) | ||
| US12343379B2 (en) | Interleukin-18 variants and methods of use | |
| Wang et al. | Breakthrough of solid tumor treatment: CAR-NK immunotherapy | |
| Barquilla et al. | Eph receptors and ephrins: therapeutic opportunities | |
| JP2016509582A5 (https=) | ||
| JP7525999B2 (ja) | キャリアー－ｐｄ－ｌ１結合剤組成物及び癌を処置する為にそれを使用する方法 | |
| Seidi et al. | NGR (Asn-Gly-Arg)-targeted delivery of coagulase to tumor vasculature arrests cancer cell growth | |
| ES2555160B1 (es) | Aptámeros específicos de TLR-4 y usos de los mismos | |
| Xiao et al. | Click reaction-assisted peptide immune checkpoint blockade for solid tumor treatment | |
| JP2013127002A5 (https=) | ||
| JP2016527286A5 (https=) | ||
| JP2013165711A5 (https=) | ||
| JP2009521206A5 (https=) | ||
| Ma et al. | Multipathway regulation for targeted atherosclerosis therapy using anti-miR-33-loaded DNA origami | |
| JP2017501130A5 (https=) | ||
| JP2016509585A5 (https=) | ||
| JP2016502515A5 (https=) | ||
| Shemesh et al. | NKp44-derived peptide binds proliferating cell nuclear antigen and mediates tumor cell death | |
| JP2015520608A5 (https=) | ||
| JP2022513421A5 (https=) | ||
| Li et al. | Staphylococcal superantigens use LAMA2 as a coreceptor to activate T cells | |
| Gahr et al. | Combination of the deacetylase inhibitor panobinostat and the multi-kinase inhibitor sorafenib for the treatment of metastatic hepatocellular carcinoma-review of the underlying molecular mechanisms and first case report | |
| D’Accardo et al. | Cancer cell targeting by CAR-T cells: A matter of stemness | |
| WO2009095925A3 (en) | Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics | |
| Hassibian et al. | Aptamers: Design, Theory, and Applications to Diagnosis and Therapy for Diseases |